The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Praise be to the bishop. More of the same please.
My prophecy yesterday fulfilled: 100000 bought next day and the price up
It's all to do with volumes. All you need is a couple of sells to cause a drop. If you were to buy 50-75 000 tomorrow the price will rise. The action will start when the rescan results are published, progress on a CE mark shows and the results come in.
Hopefully,i just can't understand the fall in the last year or so when all news coming from the company is good? One to sit on.....
No idea why the dip Tino. A wee shake of the tree before news perhaps? Watched the presentation and was convinced, am invested now - especially with the near-term catalyst and road to market. Very low mcap considering their pipeline. LTH. GL.
Can anyone advise me on why this is loosing so much, especially with such a good outlook.
I was just thinking ... no reaction in the sp to this great news, what we need is a Hardman note ... and lo one appeared as if by magic! http://hardmanandco.com/docs/default-source/company-docs/collagen-solutions-plc-documents/21.09.17-engineering-towards-ce-mark.pdf
It's good to see the chairman sticking in £46K of his own money in.....he's up to 12.15% holding. Confidence most definitely, and from somebody who knows how to make money....
From our new director, show of confidence. The first trade was my top up today , roll on next year.
25/07/2017 08:32:33 COS 5.10 O 900,000
TW: "Buy up to 6.25, target of at least 8.5." And this morning, Director share options at 10p announced.
yep , plenty . next 2 years could be interesting. GLA
Reaction today.
"With high margins, once sales go through inflection point operational gearing will see a rapid ramp up in profitability. Buy up to 6.25, target of at least 8.5." Very bullish as you can see and particularly encouraged by the CEO's words on profit targets.
Oops, just see if I can fix that link... https://youtu.be/sJwF9SHFj5U
//youtu.be/sJwF9SHFj5U " Published on 11 Jul 2017 Jamal Rushdie, chief executive of Collagen Solutions PLC (LON:COS) talks through the firm's results for the year to the end of March 2017. "
2 x 200k buys..nice
Excellent progress, slow and steady please... Financial Highlights · Group revenue and other income increased by 26% to £4.09 million (2016: £3.24 million) · Adjusted LBITDA (before separately identifiable items): £1.26 million (2016: £0.41 million) · Net cash balances at 31 March 2017: £8.98 million (2016: £2.49 million) · Balance sheet strengthened with up to £10.8 million (gross) in equity and venture debt facility Operational Highlights · Commercial organisation delivered nine new commercial agreements · Online U.S. sales launch to provide additional access to the research markets · 60% stake taken in Cre8ive Collagen to move into Chinese market · Strengthened executive team with key R&D, Sales and Marketing, and General Management hires · Provisional patent for bone graft substitute filed · Australian patent for sourcing ultra-thin processed pericardium granted · Participation in second major Horizon 2020 project
Sell on news peeps around..buyers very shortly...revenue increasing..plenty cash.
Happy with that after a quick browse , nothing stands out to worry me so ill continue to hold.
Small piece in the scotland on sunday.
The fact they signed up 15 of the original 17 patients is excellent.